Cidara Therapeutics (NASDAQ: CDTX) officer logs 10,332-share tax withholding

Rhea-AI Filing Summary

Cidara Therapeutics’ Chief Medical Officer reported a routine insider stock transaction. On 12/10/2025, 10,332 shares of common stock were disposed of to cover taxes due on restricted stock unit vesting, as explained in the footnotes. After this tax withholding, the officer beneficially owned 21,286 common shares directly, which includes 200 shares acquired through the company’s Employee Stock Purchase Plan on November 20, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davarpanah Nicole Negar

(Last) (First) (Middle)

6310 NANCY RIDGE DRIVE

SUITE 101

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cidara Therapeutics, Inc. [ CDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		F		10,332(1)	D	$219.6	21,286(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for taxes on RSU vesting.

2. Includes 200 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on November 20, 2025.

Remarks:

	/s/ Shane Ward, Attorney-in-Fact	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cidara Therapeutics (CDTX) report in this filing?

The filing shows that the Chief Medical Officer disposed of 10,332 shares of Cidara Therapeutics common stock on 12/10/2025 to cover taxes on restricted stock unit (RSU) vesting.

How many Cidara Therapeutics (CDTX) shares does the officer own after the transaction?

Following the reported tax withholding, the officer beneficially owned 21,286 shares of Cidara Therapeutics common stock directly.

Was the CDTX insider transaction an open-market stock sale?

No. The footnotes state that the 10,332 shares were withheld for taxes on RSU vesting, rather than sold in an open-market transaction.

What does the filing say about restricted stock units (RSUs) at Cidara Therapeutics?

The filing explains that shares were withheld for taxes on RSU vesting, indicating the transaction was related to equity compensation rather than a discretionary sale.

How many CDTX shares were acquired through the Employee Stock Purchase Plan?

The footnotes note that the reported beneficial ownership figure includes 200 shares acquired under Cidara’s Employee Stock Purchase Plan on November 20, 2025.

Whose ownership is reported in this Cidara Therapeutics insider filing?

The filing relates to an officer of Cidara Therapeutics, specifically the company’s Chief Medical Officer, and is filed for one reporting person.